Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Total Non-Current Liabilities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Total Non-Current Liabilities for 7 consecutive years, with $242.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Non-Current Liabilities fell 34.27% to $242.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $242.6 million, a 34.27% decrease, with the full-year FY2025 number at $242.6 million, down 34.27% from a year prior.
  • Total Non-Current Liabilities was $242.6 million for Q4 2025 at Beam Therapeutics, down from $338.4 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $616.3 million in Q4 2021 to a low of $234.0 million in Q1 2021.
  • A 5-year average of $440.3 million and a median of $425.8 million in 2024 define the central range for Total Non-Current Liabilities.
  • Peak YoY movement for Total Non-Current Liabilities: surged 399.84% in 2021, then tumbled 34.27% in 2025.
  • Beam Therapeutics' Total Non-Current Liabilities stood at $616.3 million in 2021, then decreased by 1.54% to $606.9 million in 2022, then decreased by 21.62% to $475.7 million in 2023, then dropped by 22.39% to $369.1 million in 2024, then crashed by 34.27% to $242.6 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Total Non-Current Liabilities are $242.6 million (Q4 2025), $338.4 million (Q3 2025), and $337.8 million (Q2 2025).